Rises in healthcare costs and small molecule genericisation, developments in specialty care models, and new priorities around innovation and buisness model sustainability are all posing critical questions for pharmaceutical companys - emerging models and historical players alike.
Can innovative players still succeed in this market? What does their future business model look like?
How can today's Top 10 companies fight back, while maintaining a strong balance sheet
and relevant portfolio.
Do protected, product development-focused, research-based business models have a future?
What new business models are poised
to enter the Top 10 in the next 10 years?